Physician profile
Parvez Khan
NPI 1184615205
$11,616.96
in general payments reported to CMS, 2019-2025
64 companies · $4,090 in 2025
The $4,090 reported for 2025 was more than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $112 · 2020: $87.24 · 2021: $672 · 2022: $1,668 · 2023: $2,067 · 2024: $2,920 · 2025: $4,090.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,891 · Long Term Medical Supply Or Device Loan: $1,280 · Education: $907.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,890.63 |
| Long Term Medical Supply Or Device Loan | $1,279.73 |
| Education | $907.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,312.40 | 2021-2025 | |
| Genentech USA, INC. | $632.68 | 2021-2025 | Venclexta, Polivy, Lunsumio |
| Daiichi Sankyo INC. | $478.38 | 2022-2025 | Enhertu, Datroway, Vanflyta |
| Takeda Pharmaceuticals U.S.A., INC. | $436.15 | 2021-2025 | Fruzaqla, Ninlaro |
| Pfizer INC. | $399.72 | 2019-2025 | |
| Celgene Corporation | $386.65 | 2021-2025 | Reblozyl, Pomalyst, Abecma |
| E.R. Squibb & Sons, L.L.C. | $385.64 | 2021-2025 | Opdivo, Augtyro, Opdualag |
| Merck Sharp & Dohme LLC | $371.96 | 2022-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Abbvie INC. | $369.83 | 2022-2025 | |
| Janssen Biotech, INC. | $362.54 | 2023-2025 | Imbruvica, Rybrevant, Darzalex |
| Genzyme Corporation | $360.81 | 2021-2024 | |
| Astellas Pharma US INC | $343.90 | 2022-2025 | Xtandi, Padcev |
| Gilead Sciences, INC. | $293.99 | 2022-2025 | Trodelvy |
| Eisai INC. | $260.71 | 2022-2025 | |
| Incyte Corporation | $256.24 | 2023-2025 | Jakafi, Zynyz |
Show all 64 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $229.53 | 2019-2023 | Kyprolis, Nplate, Vectibix |
| Pharmaessentia USA Corporation | $209.10 | 2023-2025 | Besremi |
| Sobi, INC | $201.36 | 2022-2025 | |
| Jazz Pharmaceuticals INC. | $183.01 | 2022-2025 | |
| Beone Medicines USA, INC. | $163.13 | 2025 | Brukinsa |
| Astrazeneca Pharmaceuticals Lp | $158.40 | 2021-2025 | Andexxa, Enhertu |
| Beigene USA, INC. | $156.88 | 2022-2025 | Brukinsa, Tevimbra |
| Exelixis INC. | $154.78 | 2022-2025 | Cabometyx |
| Glaxosmithkline, LLC. | $151.38 | 2023-2025 | Ojjaara |
| Seagen INC. | $150.48 | 2021-2025 | Padcev |
| Mylan Institutional INC. | $149.66 | 2021-2023 | Fulphila, Ogivri |
| Taiho Oncology, INC. | $132.13 | 2022-2025 | |
| Regeneron Healthcare Solutions, INC. | $109.84 | 2022-2025 | Libtayo |
| Janssen Pharmaceuticals, INC | $109.08 | 2021-2024 | Xarelto |
| Aveo Pharmaceuticals, INC. | $106.45 | 2022-2025 | Fotivda |
| Sanofi-Aventis U.S. LLC | $98.00 | 2024 | |
| Legend Biotech USA INC. | $97.80 | 2025 | Carvykti |
| Tersera Therapeutics LLC | $92.16 | 2024-2025 | Zoladex |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $87.24 | 2020 | |
| Kite Pharma, INC. | $81.70 | 2022-2024 | Yescarta |
| Array Biopharma INC | $78.94 | 2024-2025 | Mektovi, Braftovi, Tukysa |
| Pharmacyclics LLC, An Abbvie Company | $74.42 | 2021-2022 | |
| Caris Mpi, INC. | $74.21 | 2025 | Mi Cancer Seek |
| Stemline Therapeutics INC. | $68.41 | 2023-2025 | Orserdu |
| Tempus Ai, INC | $64.49 | 2024 | |
| Adc Therapeutics America, INC. | $63.05 | 2022 | |
| Lilly USA, LLC | $62.80 | 2023-2025 | Jaypirca, Verzenio |
| Emd Serono, INC. | $62.56 | 2023-2024 | Bavencio |
| Pharmacosmos Therapeutics INC. | $61.37 | 2021-2025 | Monoferric |
| Agios Pharmaceuticals, INC. | $59.25 | 2025 | Pyrukynd |
| Amag Pharmaceuticals, INC. | $50.69 | 2021-2022 | |
| Karyopharm Therapeutics INC. | $43.11 | 2023-2025 | Xpovio |
| Azurity Pharmaceuticals, INC. | $37.23 | 2025 | Danziten |
| Octapharma USA, INC. | $33.34 | 2024 | Panzyga |
| Servier Pharmaceuticals LLC | $27.72 | 2023-2025 | |
| Rigel Pharmaceuticals, INC. | $27.16 | 2022 | |
| Recordati_rare_diseases_inc. | $25.87 | 2024 | Sylvant |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.69 | 2025 | |
| Biocon Biologics INC | $24.13 | 2023 | Ogivri |
| Novocure INC. | $21.80 | 2025 | Optune Lua (Novottf-200t) |
| Blueprint Medicines Corporation | $21.73 | 2025 | Ayvakit |
| Deciphera Pharmaceuticals INC. | $20.37 | 2025 | Qinlock |
| Bayer Healthcare Pharmaceuticals INC. | $20.23 | 2023 | |
| Dova Pharmaceuticals | $17.85 | 2021 | |
| Mirati Therapeutics, INC. | $17.76 | 2024 | Krazati |
| Foundation Medicine, INC. | $16.94 | 2023 | Foundationone Cdx |
| Dendreon Pharmaceuticals LLC | $16.25 | 2024 | Provenge |
| Shield Therapeutics INC | $15.51 | 2024 | |
| Puma Biotechnology, INC. | $11.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parvez Khan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.